Antisense oligonucleotides targeting rage.
OA22367AActive Publication Date: 2026-11-04RAGE BIOTECH PTY LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- OA1202600111
- Authority / Receiving Office
- OA · OA
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2026-11-04
- Estimated Expiration
- 2044-10-18
Abstract
The present invention relates to potent spliceswitching antisense oligonucleotides that modulate alternative splicing of pre-mRNA coding for the Receptor for Advanced Glycation Endproducts (RAGE) or part thereof, and methods of treatment of RAGE-related disorders using said antisense oligonucleotides. In one aspect, the present invention provides an antisense oligonucleotide (AON) consisting of the nucleotide sequence TGCCGCCTTTGCCACAAG (5'-3'; SEQ ID NO: 1); or GCCGCCTTTGCCACAAGA (5'-3'; SEQ ID NO: 2), preferably wherein the antisense oligonucleotide comprises at least one modified nucleotide.
Need to check novelty before this filing date? Find Prior Art
